Drug Patents owned by Bausch And Lomb
1. Drug name - BESIVANCE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(8 years from now) | |
| CN102369189B | BAUSCH AND LOMB | Fluoroquinolone Carboxylic Acid Molecular Crystals |
Mar, 2030
(7 years from now) | |
| CN102369189A | BAUSCH AND LOMB | Fluoroquinolone Carboxylic Acid Molecule Crystal |
Mar, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(7 years from now) | |
| US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(7 years from now) | |
| US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(8 years from now) | |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.6% BASE | SUSPENSION/DROPS;OPHTHALMIC | Prescription |
2. Drug name - PROLENSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(2 years from now) | |
| CN100341498C | BAUSCH AND LOMB | Containing 2-Amino - -3-(4-Bromine-Benzoyl) Phenylacetic Acid Aqueous Liquid Preparation |
Jan, 2024
(1 year, 3 months from now) | |
| CN1700913A | BAUSCH AND LOMB | Containing 2-Amino - -3-(4-Bromine-Benzoyl) Phenylacetic Acid Aqueous Liquid Preparation |
Jan, 2024
(1 year, 3 months from now) | |
| EP1586316A1 | BAUSCH AND LOMB | Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid |
Jan, 2024
(1 year, 3 months from now) | |
| EP1586316A4 | BAUSCH AND LOMB | Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid |
Jan, 2024
(1 year, 3 months from now) | |
| EP1586316B1 | BAUSCH AND LOMB | Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid |
Jan, 2024
(1 year, 3 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 3 months from now) | |
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 3 months from now) | |
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 3 months from now) | |
| US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 3 months from now) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 3 months from now) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 3 months from now) | |
| US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(10 years from now) | |
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(11 years from now) | |
Drugs and Companies using BROMFENAC SODIUM ingredient
Treatment: Method of treating ocular inflammation; method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.07% ACID | SOLUTION/DROPS;OPHTHALMIC | Prescription |
3. Drug name - VYZULTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(2 years from now) | |
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(2 years from now) | |
| US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(2 years from now) | |
| CN100469765C | BAUSCH AND LOMB | Prostaglandin Nitroxide Derivative |
Dec, 2024
(2 years from now) | |
| CN1906159A | BAUSCH AND LOMB | The Prostaglandin Nitroxide Derivative |
Dec, 2024
(2 years from now) | |
| IN276779B | BAUSCH AND LOMB | Prostaglandin Nitrooxyderivatives |
Dec, 2024
(2 years from now) | |
| IN200603240P1 | BAUSCH AND LOMB | Prostaglandin Derivatives |
Dec, 2024
(2 years from now) | |
| EP1704141B1 | BAUSCH AND LOMB | Prostaglandin Nitrooxyderivatives |
Dec, 2024
(2 years from now) | |
| EP1704141A1 | BAUSCH AND LOMB | Prostaglandin Nitrooxyderivatives |
Dec, 2024
(2 years from now) | |
| EP3002277B1 | BAUSCH AND LOMB | Prostaglandin Derivatives |
Dec, 2024
(2 years from now) | |
| EP3002277A1 | BAUSCH AND LOMB | Prostaglandin Derivatives |
Dec, 2024
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(2 years from now) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.024% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.